NDAOPHTHALMICINSERT
Approved
Jun 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
LACRISERT (hydroxypropyl cellulose) by Bausch + Lomb is clinical pharmacology pharmacodynamics lacrisert acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Approved for moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. First approved in 1981.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LACRISERT is an ophthalmic insert containing hydroxypropyl cellulose, a physiologically inert polymer that stabilizes and thickens the precorneal tear film. It is indicated for moderate to severe dry eye syndromes, including keratoconjunctivitis sicca, and works by prolonging tear film breakup time while lubricating and protecting the ocular surface. The insert dissolves over 14–24 hours, providing sustained symptom relief superior to frequent artificial tear applications.
$0.017BPart D
LOE ApproachingDeclining
As a legacy product nearing loss of exclusivity with minimal Part D spend and low claim volume, the brand team is likely modest and focused on defending market share against generic and OTC alternatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics LACRISERT acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. LACRISERT also acts to lubricate and protect the eye. LACRISERT usually reduces the signs and…
Worked on LACRISERT at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.